Research Papers:

Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma

Richard Kim _, Domenico Coppola, Emilie Wang, Young Doo Chang, Yuhree Kim, Daniel Anaya and Dae Won Kim

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:23366-23372. https://doi.org/10.18632/oncotarget.25163

Metrics: PDF 1600 views  |   HTML 2507 views  |   ?  


Richard Kim1, Domenico Coppola2, Emilie Wang3, Young Doo Chang4, Yuhree Kim5, Daniel Anaya1 and Dae Won Kim1

1Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA

2Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL, USA

3Department of Internal Medicine, University of South Florida, Tampa, FL, USA

4Department of Supportive Care, Moffitt Cancer Center, Tampa, FL, USA

5Department of Population Medicine, Harvard Medical School, Boston, MA, USA

Correspondence to:

Richard Kim, email: [email protected]

Keywords: cholangiocarcinoma; tumor infiltrating lymphocytes; tumor microenvironment; PD-L1

Received: December 27, 2017     Accepted: April 02, 2018     Published: May 04, 2018


Cholangiocarcinoma is a malignancy arising from the biliary tract epithelial cells with poor prognosis. Tumor infiltrating lymphocytes (TIL)s and programmed cell death receptor ligand 1 (PD-L1) have a prognostic impact in various solid tumors. We aimed to investigate TILs and PD-L1 expression and their clinical relevance in cholangiocarcinoma. Tumor samples from 44 patients with resected and histologically verified extrahepatic cholangiocarcinoma were evaluated for CD8, CD45RO and PD-L1 expression, and their correlations with clinicopathological data and survival data were analyzed. Total 44 extrahepatic cholangiocarcinoma tissues were evaluated. CD8+ tumor infiltrating lymphocytes (TIL)s were observed in 30 (68%) tumors. Among them, 14 had CD8+CD45RO+ TILs. PD-L1 was expressed on cancer cells in 10 (22.7%) tumors in 34 evaluable extrahepatic cholangiocarciniomas. The presence of CD8+ TILs or CD8+CD45RO+ TILs was not associated with clinical staging or tumor differentiation. Extrahepatic cholangiocarcinoma with CD8+CD45RO+ TILs had longer overall survival (OS) on univariate (P = 0.013) and multivariate (P = 0.012) analysis. Neither CD8+TIL nor PD-L1 expression on cancer cells correlated significantly with OS. These results add to the understanding of the clinical features associated with CD8 TILs and PD-L1 expression in extrahepatic cholangiocarcinoma, and they support the potential rationale of using PD-1 blockade immunotherapy in cholangiocarcinoma.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25163